Aldagen, Inc announced that it has received orphan drug designation for ALD-101 from the US Food and Drug Administration (FDA). The designation was granted for the use of ALD-101 to improve patient outcomes by decreasing time to platelet and neutrophil engraftment in patients with inherited metabolic disorders undergoing umbilical cord blood transplantation.
The details can be read here.
No comments:
Post a Comment